ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Eli Lilly & Co. has licensed worldwide rights to a small-molecule transcriptional regulator for the treatment of osteoarthritis to Transition Therapeutics. Toronto-based Transition says the drug, TT-601, has completed preclinical development and can enter the clinic next year. Under the agreement, Lilly has an option to reacquire rights to TT-601 after reviewing clinical results. The two firms struck a similar deal over TT-401, a diabetes drug candidate, in 2010. Last month Lilly exercised its option to reacquire that drug.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter